학술논문

Flow Cytometric Immune Profiling in Infliximab-Associated Tuberculosis.
Document Type
Article
Source
Clinical Medicine Insights: Case Reports. 2017, Issue 10, p1-3. 3p. 1 Black and White Photograph, 1 Graph.
Subject
*TUBERCULOSIS diagnosis
*FLOW cytometry
*TUBERCULOSIS
*TUMOR necrosis factors
*ULCERATIVE colitis
*CHEMICAL inhibitors
*INFLIXIMAB
Language
ISSN
1179-5476
Abstract
Tumor necrosis factor α antagonists are increasingly used to treat inflammatory and autoimmune disorders and are associated with increased risk of active tuberculosis. Diagnosis of active tuberculosis in patients taking tumor necrosis factor α antagonists can be challenging owing to increased incidence of extrapulmonary manifestations and false-negative results on current available diagnostic tests. We present a case of a young woman on infliximab for ulcerative colitis who presented with disseminated tuberculosis. As part of a research study, we performed flow cytometric immune profiling, which has previously not been reported in patients with active tuberculosis taking tumor necrosis α antagonists. The flow cytometry results were within the positive thresholds for tuberculosis infection. Flow cytometric immune profiling may be a valid diagnostic tool for patients taking tumor necrosis factor α antagonists. [ABSTRACT FROM AUTHOR]